ARRAYJET LIMITED

Investment Risk Analysis: Arrayjet Limited (SC209936)

1. Risk Rating: HIGH

The directors have explicitly disclosed material uncertainty regarding the company's ability to continue as a going concern, citing cashflow challenges, declining sales, and global trade headwinds. Combined with a 62% year-on-year decline in cash reserves, a 75% reduction in working capital, and two recent director resignations, the risk profile is elevated. While the company has a long operating history and a specialist niche, the near-term financial trajectory is deteriorating.

2. Key Concerns

i. Going Concern Material Uncertainty The accounts state the company is "managing an extended period of cashflow challenges" and faces "material uncertainty over revenue generation and cash inflows." This is a formal flag under FRS 102 that significant doubt exists about the company's continuation. The directors' mitigation strategy—staff cuts, reduced marketing and R&D spend—may preserve cash but risks eroding the company's competitive position and revenue-generating capacity further.

ii. Rapid Deterioration in Liquidity Cash at bank fell from £439,758 (Dec 2024) to £167,030 (Dec 2025), a reduction of £272,728. Net current assets (working capital) collapsed from £371,108 to £93,249. Current liabilities rose 41% to £1,599,834 against current assets of £1,693,083, leaving a working capital buffer of under £100k. This is an extremely thin margin for a manufacturing business with stock obligations and production lead times.

iii. Director Turnover and Governance Signals Two directors resigned in 2026: Xxxxxx Xxxxxxxxname shown to subscribers (American, resigned June 2026) and Xxxxxx Xxxxxxxxname shown to subscribers (resigned February 2026). While resignations can occur for benign reasons, the timing—coinciding with disclosed financial distress—warrants scrutiny. The departure of directors during a period of material uncertainty may signal disagreement on strategic direction, loss of confidence, or broader instability within the leadership team.

3. Positive Indicators

• Established Operating History: Incorporated in 2000, the company has 25 years of trading continuity, indicating resilience and established market presence in the life-science tools sector.
• Intellectual Property Base: Intangible assets of £115,858 (patents and licences) reflect proprietary technology in microarray printing—a specialist niche with barriers to entry.
• Filing Compliance Current: Both accounts and confirmation statements are up to date with no overdue filings, indicating basic governance discipline is being maintained.
• Parent Company Ownership: Arrayjet Holdings Ltd owns 75%+ of shares, which may provide access to group-level financial support, though this is unconfirmed from available data.
• Sector Recovery Forecast: Directors cite industry-wide forecasts for growth resumption in 2026, attributing the downturn to temporary factors (NIH/FDA restructuring, tariff uncertainty) rather than company-specific failure.

4. Due Diligence Notes

1. Parent Company Financial Position: Arrayjet Holdings Ltd should be investigated as the controlling entity. Does the parent provide financial support, guarantees, or intercompany loans? The P&L reserve of approximately -£4.95M against share premium of £5.1M suggests historical capital injection without sustained profitability. Group accounts (if available) would provide critical context.

2. Debtor Quality and Aging: Debtors increased 55% from £814,106 to £1,264,036. This could indicate delayed customer payments, extended credit terms, or revenue recognition timing. An aging analysis and bad debt provision adequacy should be examined. Given the life-science tools customer base (academic and research institutions), payment cycles may be inherently long.

3. Composition of Current Liabilities: The £1,599,834 in current liabilities is not broken down in the available data. Understanding the split between trade creditors, accrued expenses, bank loans, and any related-party obligations is essential. If a significant portion is bank debt with covenants, covenant breach risk should be assessed.

4. Order Book and Revenue Pipeline: The directors state "current orders are expected to sustain the company until growth resumes." The credibility of this assertion depends on the size, timing, and conversion probability of the current order book. Requesting management accounts and forward forecasts would be essential.

5. Reasons for Director Departures: Direct enquiry should be made regarding the circumstances of Xxxxxx Xxxxxxxxname shown to subscribers's and Xxxxxx Xxxxxxxxname shown to subscribers's resignations. Were these planned transitions, or did they reflect concerns about the company's direction? Xxxxxx Xxxxxxxxname shown to subscribers's American nationality may be relevant given the cited US market headwinds (NIH/FDA restructuring).

6. Stock Valuation: Stock stands at £262,017. Given reduced R&D activity and potential product obsolescence risk in a technology-driven sector, the net realisable value assumption should be tested.

7. R&D Reduction Impact: The company has "limited discretionary spending on marketing and R&D activities." For a specialist scientific instruments manufacturer, sustained R&D underinvestment could compromise long-term product competitiveness. Assess how long this can continue before market position is irreversibly damaged.

Names of the people mentioned are shown to subscribers. See subscription